|
|||||
|
|
Novel hepato‐preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes |
|
| Authors: | Niels Porksen MD PhD Helle Linnebjerg PhD Parag Garhyan PhD Eric C. Q. Lam PhD Mary P. Knadler PhD Scott J. Jacober MD Ulrike Hoevelmann MD Leona Plum‐Moerschel MD Amalia Gastaldelli MD Tim Heise MD |
| Affiliation: | 1. Eli Lilly and Company, Departments of endocrinology, clinical pharmacology, PK/PD and drug disposition Indianapolis, Indiana;2. Lilly‐NUS Centre for Clinical Pharmacology, Department of Statistics, Singapore, Singapore;3. Profil, Neuss, Germany;4. Cardiometabolic Risk Unit, Institute of Clinical Physiology, National Research Council (CNR), Pisa, Italy |
| Abstract: | |
| Keywords: | basal insulin drug mechanism insulin resistance Phase 1 to 2 study type 1 diabetes type 2 diabetes |